Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely…
The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…
Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor necrosis factor-alpha (TNF…
Friedreich’s ataxia (FA) is a progressive, autosomal recessive, neurodegenerative disease characterized by slowly advancing ataxia (loss of bodily control). No treatments are currently approved…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…
Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…
MARKET OUTLOOK The moderate to severe AD market is at the beginning of a revolution with the recent approval of the first targeted AD biologic, Sanofi/Regeneron’s Dupixent, and a promising…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…
Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs). It is characterized by an irreversible loss of lung function, leading to…
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…